BioSante Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement

BioSante Pharmaceuticals, Inc.

announced today that it has received notice from The NASDAQ Stock Market indicating that BioSante has regained compliance with the minimum bid price requirement for continued inclusion of its common stock on The NASDAQ Global Market. As previously announced by BioSante on June 11, 2012 the Company plans to initiate two new LibiGel Phase III efficacy trials. This decision is based on an extensive analysis of previous efficacy data, consultation with key opinion leaders (KOLs) in female sexual dysfunction, testosterone therapy and placebo effects, as well as a meeting with the U.S. Food and Drug Administration (FDA). BioSante also intends to continue the on-going LibiGel Phase III cardiovascular and breast cancer safety study as per protocol. LibiGel (testosterone gel) is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women.